Know Cancer

forgot password

A Phase 1 Study of AC220 (ASP2689) in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1
18 Years
60 Years
Open (Enrolling)
Leukemia, Myeloid, Acute

Thank you

Trial Information

A Phase 1 Study of AC220 (ASP2689) in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Subjects will receive escalating doses of AC220 plus standard 7+3 cytarabine and
daunorubicin remission induction therapy. Subjects may receive up to 2 cycles of induction
therapy. Subjects who have a complete response (including complete remission (CR) with
incomplete hematologic recovery) are eligible to receive up to 3 consolidation cycles. In
consolidation subjects will receive AC220 plus high dose cytarabine.Subjects achieving a
composite Complete Remission (CRc) will be eligible to receive AC220 alone for up to 12
additional 28 day cycles.

Subjects will be enrolled into successive gender balanced cohorts of 6 subjects (at least 3
must be females) to determine the maximum tolerated dose (MTD). Dose escalation decision
will be made based on dose limiting toxicities (DLTs) that occur during the first remission
induction cycle. Seven and 14 day schedules will be evaluated.

After the MTD and schedule is established, the study will open to enroll between 14 to 34
subjects. Subjects will receive AC220 during induction and consolidation at the MTD and
schedule established. Stopping rules will be used to evaluate safety at the current dose.
If testing at a dose level must be stopped, then a lower dose may be tested. MTD will also
be established for the maintenance therapy.

Inclusion Criteria:

- Subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML)
according to World Health Organization (WHO) classification (2008) documented within
28 days prior to enrollment and defined as > 20% myeloblasts on the marrow aspirate
or peripheral blood differential, with or without extramedullary involvement, with
confirmatory immunophenotyping or immunocytochemistry (e.g. myeloperoxidase). In
addition, subjects with the clonal, recurring cytogenetic abnormalities:
t(8;21)(q22;q22), inv(16)(p13q22) or t(16;16)(p13;q22) should be considered to have
AML regardless of the blast percentage. Subjects with both positive and negative
FMS-like tyrosine kinase - internal tandem duplication (FLT3-ITD) mutation status
are eligible.

- Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

- Subject must have adequate renal, hepatic, and coagulation parameters as indicated by
the following laboratory values:

- Alkaline phosphatase, AST, ALT ≤ 2.5 x institutional upper limit of normal (ULN)

- Total bilirubin ≤ 1.5 x institutional ULN

- Serum creatinine ≤ 1.5 x institutional ULN or an estimated glomerular filtration
rate (eGFR) of >50 ml/min as calculated by the Modification of Diet in Renal
Disease (MDRD) equation.

- Subject is a woman of childbearing potential (WOCBP) or a male subject with female
partner of childbearing potential who agrees to use a medically-approved method of
contraception to avoid pregnancy throughout the study and for at least 3 months after
the last dose of study drug.

- Subject is a WOCBP and has a negative serum or urine pregnancy test (sensitivity ≤ 25
IU human chorionic gonadotropin [hCG]/L) within 72 hours prior to the start of study
drug administration.

- Subject is able to comply with study procedures and follow-up examinations.

Exclusion Criteria:

- Subject has a diagnosis of acute promyelocytic leukemia (APL),
French-American-British (FAB) classification M3 or World Health Organization (WHO)
classification of APL with t(15;17)(q22;q12), or BCR-ABL positive leukemia (chronic
myelogenous leukemia in blast crisis).

- Subject has a diagnosis of AML following an antecedent hematologic disorder
(diagnosis of myelodysplasia or myeloproliferative neoplasm by bone marrow aspirate
and/or biopsy documented at least 12 weeks prior to first dose of study drug).

- Subject has a diagnosis of acute bilineal/biphenotypic leukemia.

- Subject has therapy-related AML.

- Subject received previous treatment with AC220.

- Subject has received previous therapy for AML, with the exception of the following:

- Emergency leukapheresis;

- Emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 5 days;

- Growth factor or cytokine support;

- Steroids for the treatment of hypersensitivity or transfusion reactions.

- Subject has uncontrolled disseminated intravascular coagulation.

- Subject has Central Nervous System (CNS) leukemia. A Subject with symptoms suggestive
of CNS leukemia must undergo a lumbar puncture; and subject with a positive
cerebrospinal fluid (CSF) for AML blasts is not eligible.

- Subject has a known positive test for human immunodeficiency virus, hepatitis C, or
hepatitis B surface antigen.

- Subject had major surgery within 4 weeks prior to the start of study drug.

- Subject has uncontrolled or significant cardiovascular disease, including

- A myocardial infarction within 12 months prior to the start of study drug;

- Uncontrolled angina within 6 months prior to the start of study drug;

- History of congestive heart failure (CHF) New York Heart Association (NYHA)
class 3 or 4,unless a screening echocardiogram (ECHO) or Multiple Gate
Acquisition Scan (MUGA) performed either within 1 month prior to or during study
screening results in a left ventricular ejection fraction (LVEF) that is ≥ 45%
(or institutional lower limit of normal value);

- Heart rate < 50 beats per minute

- Diagnosed or suspected congenital long QT syndrome;

- Any history of clinically significant ventricular arrhythmias (such as
ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes [TdP])
(any other history of arrhythmia will be discussed with the Sponsor's Medical
Monitor prior to subject's entry into the study);

- QTc interval calculated by Fridericia's correction factor (QTcF) pre-AC220 dose
≥ 450 ms. The QTcF will be derived from the average QTcF in triplicate;

- Any history of second or third degree heart block;

- Uncontrolled hypertension defined as systolic blood pressure ≥ 180 mmHg or
diastolic blood pressure ≥ 110 mmHg;

- Obligate need for a cardiac pacemaker or defibrillator;

- Complete left bundle branch block; or

- Atrial fibrillation documented within 2 weeks prior to first dose of study drug.

- Subject has a pre-existing disorder predisposing the subject to a serious or
life-threatening infection (e.g. cystic fibrosis, congenital or acquired
immunodeficiency, bleeding disorder, or cytopenias).

- Subject has an active acute or chronic systemic fungal, bacterial, viral, or other

- Subject has a concurrent disease (e.g. a history of serious organ dysfunction or
disease) that may place the subject at undue risk to undergo induction therapy per
protocol, or that might obscure assessments of drug safety.

- Subject requires treatment with concomitant drugs that prolong QT/QTc interval or
strong cytochrome P-3A4 (CYP3A4) inhibitors or inducers with the exception of
antibiotics, antifungals, and antivirals that are used as standard of care to prevent
or treat infections and other such drugs that are considered absolutely essential for
the care of the subject.

- Subject requires treatment with anticoagulant therapy.

- Subject is a female who is lactating.

- Subject has any medical, psychiatric, addictive or other kind of disorder which
compromises the ability of the subject to give written informed consent and/or to
comply with procedures.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety assessed by recording adverse events, physical examinations, vital signs, electrocardiograms (ECGs), and laboratory assessments

Outcome Time Frame:

up to Day 42

Safety Issue:


Principal Investigator

Senior Medical Director

Investigator Role:

Study Director

Investigator Affiliation:

Astellas Pharma Global Development


United States: Food and Drug Administration

Study ID:




Start Date:

October 2011

Completion Date:

March 2014

Related Keywords:

  • Leukemia, Myeloid, Acute
  • AC220
  • Acute Myeloid Leukemia (AML)
  • De Novo Acute Myeloid Leukemia (AML)
  • Newly diagnosed Acute Myeloid Leukemia (AML)
  • FMS-like tyrosine kinase (FLT3)
  • FMS-like tyrosine kinase (FLT3) Inhibitor
  • Kinase
  • Kinase Inhibitor
  • Pharmacokinetics
  • ASP2689
  • quizartinib
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid



Mayo Clinic Jacksonville Jacksonville, Florida  32224
Northwestern University Chicago, Illinois  60611
M.D. Anderson Cancer Center Houston, Texas  77030
Johns Hopkins Medical Institute Baltimore, Maryland  21231
Memorial-Sloan Kettering Cancer Center New York, New York  10021-6007